An evaluation of the cGMP manufacturing process economics and high-throughput characterisation of Targeted Secretion Inhibitors by Hooker, A et al.
AN EVALUATION OF THE cGMP MANUFACTURING PROCESS ECONOMICS AND HIGH-
THROUGHPUT CHARACTERISATION OF TARGETED SECRETION INHIBITORS 
 
Andy Hookera*, Andrew Splevinsa, Peter Horrocksa, Paul Dalbyb, Suzanne Faridb 
 
aIpsen Bioinnovation Limited, Oxford, UK;  bUniversity College London, London, UK 
 
*Corresponding author:  Ipsen Bioinnovation Limited, Oxford, OX14 4RY, UK. 
E-mail address:  andy.hooker@ipsen.com 
 
 
Introduction and Objectives: 
Targeted Secretion Inhibitors (TSIs) are a novel class of recombinant biotherapeutics, using 
protein engineering to re-target Botulinum neurotoxins for treatment of diseases with 
secretion disorders. SXN101959 has been successfully manufactured by Ipsen to cGMP 
standards and is an example of an emerging recombinant TSI manufacturing platform. 
SXN101959 is a multi-domain, multi-functional recombinant protein expressed within 
Escherichia coli, composed of a light chain (LC/D) endopeptidase domain and a heavy chain 
(HN/D) domain with a growth hormone releasing hormone (GHRH) targeting peptide ligand. 
 
The Engineering and Physical Sciences Research Council (EPSRC) within the UK has established a 
Centre for Innovative Manufacturing in Emergent Macromolecular Therapies at University 
College London. The Centre provides an international lead in delivering biopharmaceutical 
manufacturing innovations for next generation advanced therapies, which has included an 
evaluation of SXN101959. We present an assessment of SXN101959 using two research 
workstreams: 
Workstream 1 – an assessment of the process economics and manufacturability of SXN101959, 
including cost of goods; and 
Workstream 2 – the development of rapid biophysical characterisation decisional tools that 
assess aggregation propensity and facilitate formulation development. 
 
 
Methods: 
Workstream 1: Process and economic data from the cGMP manufacturing of SXN101959 were 
collated and combined into a spreadsheet-based mathematical model, in order to determine 
the key cost factors and allow future improvements that would reduce manufacturing costs. 
 
Workstream 2: The aggregation properties of SXN101959 were studied by Size Exclusion High 
Performance Liquid Chromatography (SE-HPLC), Static Light Scattering (SLS), Intrinsic 
Fluorescence and monitoring binding of fluorescent dyes.  These studies were performed in 
various buffers. 
 
  
Results and Conclusions: 
We present the key outcomes from the two SXN101959 research workstreams: 
Workstream 1: Successful generation of a mathematical spreadsheet-based tool, able to 
identify key costs in the manufacturing process, and estimate effects of manufacturing scale on 
costs of goods; and 
Workstream 2: A suite of analytical tools able to provide data on the aggregation propensity of 
SXN101959, and so identify solvent conditions for minimizing aggregation. 
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